Immune-response markers and actual response to immune-oncology therapy in uterine serous carcinoma


Nathaniel L. Jones, Sharon Wu, Joanne Xiu, Amaranta Craig, Gina Mantia-Smaldone, Enrique Hernandez, Rodney Paul Rocconi, Jubilee Brown, Thomas J. Herzog, Robert W. Holloway, Wolfgang Michael Korn, Matthew A. Powell, Annelise M Wilhite

Background: Uterine serous carcinoma (USC) is an aggressive subtype of endometrial cancer with poor prognosis and limited treatment options. Immune-oncology (IO) agents have shown promise USC, however data is limited regarding which patients benefit most from IO therapy. In other malignancies, PD-L1, MSI-H status and high TMB have been predictive of IO response. We sought to characterize the immune profiles of USC and investigate treatment response to IO therapy.

Download Publication